NASDAQ: PTCT

PTC Therapeutics (PTCT) Stock Analysis & Forecast

Nov 13 close

$63.49+0.13 (+0.2%)

Gekko Brief

AI summaryNov 9 close

PTC Therapeutics' board has authorized a share repurchase program of up to $500 million, announced alongside continued attention on Sephience's launch, which has been offsetting declines in legacy products. Commentary this week has been mixed: one view describes the stock as roughly fairly valued around a P/S ratio of 5.0x, while another rates it Hold, bordering on Sell, with a fair value estimate near $52 per share against its own cited price. Shareholders remain down 20.7% year-to-date according to one recap, even as the company has pointed to record revenue and raised guidance earlier in the year.

PTCT closed at $65.03, down 0.6%, sitting between its 50-day average of $64.67 and 200-day average of $70.40. The GekkoIndex reads 55.5, placing the stock in the Neutral zone, down 6.9 over five days. Price sits 17.7% below Gekko Fair Value of $78.97. Over the past three and six months, shares have declined 11.8% and 15.4% respectively, with a 52-week range of $58.80 to $90.87.

The next earnings report is scheduled for 18 February 2027, 100 days out and beyond a typical 20-day holding window. No insider, Congress, or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged a 10.7% return over 5 years, rising in 4 of them. Analyst coverage from 12 firms shows 10 Buy and 2 Hold ratings, with a consensus target of $100.47. Upcoming investor conference appearances on 16 November and 1 December are also worth noting.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

PTC Therapeutics price vs fair value

$78.46$63.49Nov ’25May ’26Nov ’26
Close $63.49200-day averageGekko Fair Value $78.46

PTC Therapeutics quick facts

Market cap
$5.30B
P/E ratio
—
Forward P/E
19.4
EPS, TTM
−$1.47
Revenue, TTM
$1.16B
Profit margin
-9.2%
Dividend yield
—
Beta
0.51
Volume
502,867 avg 1.07M
1-year return
−15.3%
Typical daily move
±4.6%
Typical 20-day move
±8.7%
50-day average
$64.12
200-day average
$70.16
Next earnings
Feb 18 after close
Shares outstanding
83.54M
52-week range
$58.80$90.87

PTC Therapeutics swing-trade checklist

PTC Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendheadwind

    Below 50 and 200-day

    Close $63.49 is below the 50-day ($64.12) and 200-day ($70.16) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexmixed

    58, Neutral

    Reading 58 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    19.1% below

    Price is 19.1% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 95 days

    Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +9.5% on average

    From this point in the calendar, the next 20 trading days averaged +9.5% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

PTC Therapeutics stock chart and price history

PTC Therapeutics closed at $63.49 on Nov 13, 2026, −15.3% over the past year, inside a 52-week range of $58.80 to $90.87.

Close50-day average200-day averageVolume
PTC Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$60$70$80$90DecJan 2026FebMarAprMayJunJulAugSepOctNov63.49

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+4.1%
3 months
−12.9%
6 months
−11.2%
1 year
−15.3%
The full PTCT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PTCT in Gekko

Follow PTC Therapeutics through every session

Put PTCT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track PTCT in GekkoFree for 7 days. No credit card required.

About PTC Therapeutics

PTC Therapeutics develops medicines for people with rare genetic disorders, working across early research, preclinical studies and clinical trials. The company is known for treatments aimed at Duchenne muscular dystrophy, including Translarna and Emflaza, which reach patients in the European Economic Area, the United States, and, in the case of Translarna, Brazil and Russia for a nonsense mutation form of the disease.

Beyond its Duchenne-focused products, the company sells Tegsedi and Waylivra for other rare conditions across Latin America and the Caribbean, and distributes Evrysdi in Brazil for spinal muscular atrophy in patients two months and older. It also uses a proprietary splicing platform to advance PTC518, a candidate being studied for Huntington's disease. Its work is supported by collaborations, including ones with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., the Spinal Muscular Atrophy Foundation, and Akcea Therapeutics, Inc., the last of which relates to commercializing Tegsedi and Waylivra in Latin America and the Caribbean.

PTC Therapeutics was established in 1998 and is headquartered in South Plainfield, New Jersey. Its shares are listed on the NASDAQ under the ticker PTCT.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
ptcbio.com

PTC Therapeutics GekkoIndex: the smart money zone

PTC Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58, in the Neutral zone, up 3.3 points over five sessions.

010058Neutral

Up 3.3 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying33+2.9%+6.1%+6.3%+8.5%
Accumulation204+1.7%+3.1%+5.3%+12.2%
Neutral (current zone)414+0.6%+0.7%+2.4%+6.9%
Distribution50−1.7%0.0%−0.8%+1.2%
Selling1Too few readings yet

Average PTCT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the PTCT price, zone by zone.Track PTCT in Gekko

Is PTC Therapeutics stock overvalued? Gekko Fair Value

PTC Therapeutics trades 19.1% below Gekko Fair Value of $78.46, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what PTC Therapeutics shares are worth, recalculated every trading day.

$78.46

Gekko Fair Value, Nov 14, 2026

19.1% Undervalued

At the end of Aug 2026 the price was 23.9% below the estimate.

Gekko Fair ValueShare price, month end
$78$63Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open PTCT in Gekko

PTC Therapeutics insider and Congress trading

No open-market insider purchases were filed for PTC Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for PTCT in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every PTCT insider filing, plotted on the chart in Gekko.Open PTCT in Gekko

Congress trades last 90 days

No trades in PTCT were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for PTCT, plotted on the chart in Gekko.Open PTCT in Gekko

Buybacks

Latest authorization
$500.0M, Nov 3, 2026

From company filings.

Hedge funds and billionaires quarter ended Sep 30

0of the funds Gekko tracks hold PTCT.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

PTC Therapeutics earnings: next date and track record

PTC Therapeutics reports on Feb 18, 2027, after the close (95 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±6.3%average move across the report
6 of 8reports followed by a gain

Share-price move across each report

+2.5%Nov ’24+8.4%Feb ’25+0.3%May ’25−11.6%Aug ’25+5.7%Nov ’25+2.5%Feb ’26+10.7%May ’26−8.7%Jul ’26
ReportedEPSSurpriseRevenueSurpriseMove
Jul 30, 2026$0.92
est $0.24
+289.3%$360.5M
est $298.6M
+20.7%−8.7%
May 7, 2026−$0.03
est −$0.45
+93.3%$272.6M
est $217.4M
+25.4%+10.7%
Feb 19, 2026−$1.67
est −$0.21
−695.2%$164.7M
est $279.5M
−41.1%+2.5%
Nov 4, 2025$0.20
est −$1.19
+116.8%$211.0M
est $281.5M
−25.0%+5.7%
Aug 7, 2025−$0.83
est −$1.07
+22.4%$178.9M
est $191.5M
−6.6%−11.6%
May 6, 2025$10.04
est −$1.08
+1,029.6%$1.18B
est $372.6M
+215.6%+0.3%
Feb 27, 2025−$0.85
est −$1.12
+24.1%$213.2M
est $232.4M
−8.3%+8.4%
Nov 7, 2024−$1.39
est −$1.44
+3.5%$196.8M
est $190.5M
+3.3%+2.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

PTC Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for PTC Therapeutics is $100.47, +58.2% from the last close, from 12 firms rating the stock in the last 90 days.

$100.47consensus 12-month target, +58.2% from the last close
Low $62High $137
Buy10
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 12 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 2BarclaysBuy, maintained$122+92.2%
Nov 2CitiBuy, maintained$109+71.7%
Nov 2J.P. MorganBuy, reiterated$92+44.9%
Oct 30Wells FargoBuy, maintained$112+76.4%
Oct 30UBSBuy, maintained$90+41.8%
+2.4%average 20-day move after past Neutral readings
+9.5%average move over the next 20 trading days in the last 5 years
±4.6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

PTC Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, PTC Therapeutics averaged +9.5% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

−4.6%2021+5.7%2022+37.3%2023+9.4%2024+1.3%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+2.8%4 of 5
Next 10 trading days+4.5%4 of 5
Next 15 trading days+8.3%4 of 5
Next 20 trading days+9.5%4 of 5
Next 30 trading days+8.7%4 of 5

For scale, PTCT’s typical 20-trading-day move in either direction is about 8.7%.

PTC Therapeutics market cap and key statistics

PTC Therapeutics’s market cap is $5.30B and revenue of $1.16B over the last twelve months.

Valuation

Market cap
$5.30B
Forward P/E
19.4
EPS, TTM
−$1.47
Gekko Fair Value
$78.46

Trading

Volume
502,867
Avg volume, 20 days
1.07M
52-week high
$90.87
52-week low
$58.80
Shares outstanding
83.54M

Financials

Revenue, TTM
$1.16B
Profit margin
-9.2%
Return on equity
-7740%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.51
Typical daily move
±4.6%
Typical 20-day move
±8.7%

PTC Therapeutics stock news this week

2 headlines about PTC Therapeutics from the past week, newest first, each linking to the publisher.

PTC Therapeutics peers

PTC Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

PTC Therapeutics stock FAQ

What is PTC Therapeutics’s market cap?

PTC Therapeutics’s market cap is $5.30B at the Nov 13, 2026 close of $63.49, with 83.54M shares outstanding.

What is the PTC Therapeutics stock forecast?

The consensus analyst 12-month price target for PTC Therapeutics is $100.47, +58.2% from the last close. Of the 12 firms that rated the stock in the last 90 days, 10 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is PTC Therapeutics stock overvalued or undervalued?

On Gekko’s estimate PTC Therapeutics is undervalued: the Nov 13, 2026 close of $63.49 is 19.1% below Gekko Fair Value of $78.46. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does PTC Therapeutics report earnings next?

PTC Therapeutics is expected to report on Feb 18, 2027, after the market closes (95 days away). Analysts expect earnings of $0.35 per share on revenue of $330.4M. PTC Therapeutics beat the earnings estimate in 7 of its last 8 reports, moving 6.3% on average across the report.

What is PTC Therapeutics’s 52-week high and low?

PTC Therapeutics’s 52-week high is $90.87 and its 52-week low is $58.80; it closed at $63.49 on Nov 13, 2026, −15.3% over the past year.

Is PTC Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (fair value, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See PTC Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.